Envisia Therapeutics
closedBiotechnology company focused on the research and development of novel ocular therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $16.5m | Series A | |
| Total Funding | 000k | ||
Related Content
Envisia Therapeutics operated as a clinical-stage biotechnology company, focusing on the development of extended-release ophthalmic therapies. The company was established in 2013 as a spin-out from Liquidia Technologies, launching with a significant $25 million Series A financing round. This initial funding was provided by investors including Canaan, New Enterprise Associates, and Wakefield Group. The company's operations were based in Research Triangle Park, North Carolina.
The core of Envisia's strategy was its proprietary PRINT (Particle Replication In Non-Wetting Templates) technology. This platform was engineered to create precisely manufactured, fully biodegradable particles for sustained drug delivery directly to the eye, addressing major ocular diseases. The technology allowed for the creation of injectable implants and suspensions capable of releasing therapeutics over several months from a single administration, thereby aiming to solve the prevalent issue of poor patient compliance with daily eye drops.
Envisia’s product pipeline targeted the leading causes of preventable blindness. Its lead candidate, ENV515, was a biodegradable travoprost implant for glaucoma, designed to lower intraocular pressure for more than six months. The company initiated a Phase 2a clinical trial for ENV515 in early 2015. Another key product in development was ENV1105, a dexamethasone implant for treating diabetic macular edema. In October 2017, Aerie Pharmaceuticals acquired the rights to Envisia's PRINT technology for use in ophthalmology, along with other assets including the ENV1105 candidate, for an upfront payment of $25 million. This event marked a significant milestone, leading to Envisia's status as being out of business following the asset acquisition.
Keywords: Envisia Therapeutics, ocular therapies, extended-release, ophthalmic, PRINT technology, glaucoma, diabetic macular edema, travoprost, ENV515, dexamethasone, drug delivery, particle replication, Liquidia Technologies, Aerie Pharmaceuticals, clinical-stage biotechnology, intraocular pressure, biodegradable implant, sustained release
